TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $57.95 million. The enterprise value is $64.35 million.
Important Dates
The last earnings date was Monday, August 11, 2025, after market close.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 39.55 million shares outstanding. The number of shares has increased by 58.23% in one year.
| Current Share Class | 39.55M |
| Shares Outstanding | 39.55M |
| Shares Change (YoY) | +58.23% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 7.99% |
| Owned by Institutions (%) | 32.75% |
| Float | 18.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.76 |
| Forward PS | 0.63 |
| PB Ratio | 6.31 |
| P/TBV Ratio | 7.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.19, with a Debt / Equity ratio of 4.51.
| Current Ratio | 3.19 |
| Quick Ratio | 2.42 |
| Debt / Equity | 4.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.40 |
Financial Efficiency
Return on equity (ROE) is -676.41% and return on invested capital (ROIC) is -48.35%.
| Return on Equity (ROE) | -676.41% |
| Return on Assets (ROA) | -36.47% |
| Return on Invested Capital (ROIC) | -48.35% |
| Return on Capital Employed (ROCE) | -76.89% |
| Revenue Per Employee | $360,397 |
| Profits Per Employee | -$195,057 |
| Employee Count | 209 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 1.96 |
Taxes
| Income Tax | -59,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.47% in the last 52 weeks. The beta is 0.93, so TELA Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -63.47% |
| 50-Day Moving Average | 1.86 |
| 200-Day Moving Average | 2.12 |
| Relative Strength Index (RSI) | 35.85 |
| Average Volume (20 Days) | 82,619 |
Short Selling Information
The latest short interest is 448,140, so 1.13% of the outstanding shares have been sold short.
| Short Interest | 448,140 |
| Short Previous Month | 470,406 |
| Short % of Shares Out | 1.13% |
| Short % of Float | 2.40% |
| Short Ratio (days to cover) | 7.28 |
Income Statement
In the last 12 months, TELA Bio had revenue of $75.32 million and -$40.77 million in losses. Loss per share was -$1.05.
| Revenue | 75.32M |
| Gross Profit | 51.08M |
| Operating Income | -37.27M |
| Pretax Income | -40.30M |
| Net Income | -40.77M |
| EBITDA | -36.21M |
| EBIT | -37.27M |
| Loss Per Share | -$1.05 |
Full Income StatementBalance Sheet
The company has $34.98 million in cash and $41.38 million in debt, giving a net cash position of -$6.41 million or -$0.16 per share.
| Cash & Cash Equivalents | 34.98M |
| Total Debt | 41.38M |
| Net Cash | -6.41M |
| Net Cash Per Share | -$0.16 |
| Equity (Book Value) | 9.18M |
| Book Value Per Share | 0.23 |
| Working Capital | 41.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.14 million and capital expenditures -$532,000, giving a free cash flow of -$34.68 million.
| Operating Cash Flow | -34.14M |
| Capital Expenditures | -532,000 |
| Free Cash Flow | -34.68M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
Gross margin is 67.81%, with operating and profit margins of -49.48% and -54.12%.
| Gross Margin | 67.81% |
| Operating Margin | -49.48% |
| Pretax Margin | -54.20% |
| Profit Margin | -54.12% |
| EBITDA Margin | -48.07% |
| EBIT Margin | -49.48% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.23% |
| Shareholder Yield | -58.23% |
| Earnings Yield | -70.35% |
| FCF Yield | -59.84% |
Analyst Forecast
The average price target for TELA Bio is $6.00, which is 309.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 309.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 24.90% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |